Hado Therapeutics is pleased to announce its formal collaboration with the University of Bradford, gaining strategic access to the world-class research environment at the Institute of Cancer Therapeutics (ICT) and the business development support of the Bradford-Renduchintala Enterprise Ecosystem (BREE).
This partnership places Hado at the heart of a thriving biomedical research and enterprise hub, providing both the scientific infrastructure and entrepreneurial resources needed to drive long-term innovation in oncology, haematology, and neurodegeneration.
“Being embedded within the Institute of Cancer Therapeutics gives us immediate access to advanced labs, specialist oncology expertise, and a collaborative academic environment,” said Dr Harsha Kantamneni, CEO of Hado Therapeutics. “Pairing that with the enterprise support from BREE creates a powerful foundation for sustainable growth and long-term impact.”
By establishing its base within the Institute of Cancer Therapeutics (ICT), Hado Therapeutics gains direct access to world-class cancer research teams with deep expertise in medicinal chemistry, pharmacology, and preclinical modelling. The company benefits from state-of-the-art laboratories and advanced screening platforms, enabling efficient and rapid drug development. The collaborative academic environment further accelerates translational science, fostering innovation at every stage of the process.
In parallel, support from the BREE provides Hado with a comprehensive commercialisation framework. This includes tailored mentoring, strategic business development guidance, and access to funding networks, venture partners, and innovation grants. Additionally, BREE offers expert advice on intellectual property, investor readiness, and long-term growth planning.
This integrated research–enterprise model directly supports Hado’s mission to build a scalable and investable biotech venture, with a focus on delivering impactful therapies for hard-to-treat conditions such as glioblastoma.
“Our goal is to create transformative therapeutics through strong science and smart execution,” Dr Kantamneni added. “Bradford offers both—cutting-edge research and real-world enterprise backing.”
About Hado Therapeutics
Hado Therapeutics Ltd (UK Reg. 12240559), formerly known as Haiku Therapeutics, based at the Institute of Cancer Therapeutics, University of Bradford. Hado is a UK-based research company specialising in the development of precision medicines for high-risk and under-treated conditions. With core expertise in oncology, haematology, and neurodegeneration, the company is advancing a pipeline of innovative therapeutics that target the underlying biological mechanisms of complex diseases, driven by strong academic and clinical partnerships.Media & Investor Contact:
📩 team@hadotherapeutics.co.uk🌐 www.hadotherapeutics.co.uk
This announcement may contain forward-looking statements. Actual outcomes depend on clinical development and collaborative outcomes.